<a href="https://laohu8.com/S/PYXS">Pyxis Oncology</a> Reports <a href="https://laohu8.com/S/QTWO">Q2</a> 2025 Revenues of $2.8M, Net Loss Widens to $18.4M, EPS at ($0.30)
Pyxis Oncology Inc. reported financial results for the second quarter of 2025, with revenues reaching $2.8 million, a significant increase from $0 in the same quarter of 2024. This revenue was primarily generated from a $3 million milestone related to the regulatory approval of suvemcitug in China, partially offset by $0.2 million in taxes. The company's net loss for the quarter ended June 30, 2025, was $18.4 million, compared to a net loss of $17.3 million in the corresponding quarter of the previous year. Excluding non-cash stock-based compensation expenses, the net loss stood at $15.3 million for the quarter, compared to $14.4 million in the prior year. Research and development expenses increased to $17.1 million from $14.0 million year-over-year, driven by heightened manufacturing and clinical trial-related expenses. Conversely, general and administrative expenses decreased to $5.4 million from $6.1 million, owing to reductions in corporate insurance, facilities costs, and professional fees. As of June 30, 2025, Pyxis Oncology had cash, cash equivalents, and short-term investments totaling $90.4 million. The company anticipates that this financial position will support its operational needs into the second half of 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pyxis Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9512730-en) on August 14, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.